Withdrawn study sought to predict who benefits from obesity drug combo

NCT ID NCT06619015

Terminated Knowledge-focused Sponsor: Esbjerg Hospital - University Hospital of Southern Denmark Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study aimed to see if adding pramlintide to semaglutide (Wegovy) could change appetite and eating habits in obese people with prediabetes. It also tried to find ways to predict who would respond best to obesity medication. The trial was withdrawn before any participants were enrolled, so no results were obtained.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pramlintide and semaglutide
What this could lead to: If it had succeeded, this study could have pointed toward more personalized obesity treatments by identifying who responds best to certain drug combinations.
What could go wrong: The study was withdrawn before enrolling anyone, so no results are available. Even if conducted, it was small (40 people) and only lasted 26 weeks, making it too early to draw broad conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for APPETITE REGULATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

APPETITE REGULATION OBESITY PREDIABETES

Contacts and locations

Locations

University hospital of Southern Denmark

Esbjerg, 6700, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.